ABSTRACT-During sepsis, systemic inflammation is observed and is associated with multiple organ failure. Activation of NF-kB is crucial for inducing inflammation, which is controlled by degradation of inhibitor molecules (IkB). The ubiquitination proteasome pathway is responsible for the regulation of protein turnover. In this study, we hypothesized that administration of 4[4-(5-nitro-furan-2-ylmethylene)-3, -dioxo-pyrazolidin-1-yl]-benzoic acid ethyl ester (PYR-41), an inhibitor of ubiquitination, could reduce inflammation and organ injury in septic mice. PYR-41 prevented the reduction of IkB protein levels and inhibited release of tumor necrosis factor (TNF)-a in mouse macrophage RAW264.7 cells at 4 h after lipopolysaccharide stimulation dose-dependently. Male C57BL/6 mice were subjected to cecal ligation and puncture (CLP) to induce sepsis. PYR-41 (5 mg/ kg) or dimethyl sulfoxide in saline (vehicle) was injected intravenously immediately after CLP. At 20 h after CLP, PYR-41 treatment significantly decreased serum levels of proinflammatory cytokines (TNF-a, interleukin [IL]-1b, and IL-6) and organ injury markers (aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase). PYR-41 significantly improved microscopic structure, and reduced myeloperoxidase activity, number of apoptotic cells and caspase-3 degradation in the lungs of septic mice. The reduced protein levels of IkB in the lungs after CLP were restored by PYR-41 treatment. PYR-41 inhibited the expression of cytokines (IL-1b and IL-6), chemokines (keratinocyte-derived chemokine and macrophage inflammatory protein 2), and inflammatory mediators (cyclooxygenase-2 and inducible nitric oxide synthase) in the lungs of septic mice. Importantly, PYR-41 significantly increased 10-day survival in septic mice from 42% to 83%. Therefore, targeting ubiquitination by PYR-41 to inhibit NF-kB activation may represent a potential strategy of sepsis therapeutics.
INTRODUCTION
Sepsis is one of the most prevalent medical conditions and accounts for 20% of admissions to intensive care units (1) . In the United States, more than 750,000 people develop sepsis each year, of whom at least 225,000 die (2, 3) . Despite numerous efforts to advance the understanding of sepsis progression, including more than 30 failed clinical trials, there is still no effective pharmacotherapy available to treat sepsis (4) (5) (6) . Clearly, there is an urgent, unmet medical need to identify and develop a new class of therapeutic agents against sepsis.
The pathophysiology of sepsis is complex. Recent consensus definitions state that sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection (7) . During the early phase of sepsis, patients present with an exaggerated, hyperinflammatory immune response, also described as a ''cytokine storm'' (8) . Such massive cytokine production can be triggered by exogenous pathogen-associated molecular pattern molecules (PAMPs) from invading microorganisms, or by endogenous damage-associated molecular pattern molecules (DAMPs) released from injured host cells (9, 10) . Both PAMPs and DAMPs bind to various types of receptors in immune cells and activate several signaling pathways, and in particular the NF-kB pathway, to stimulate the production of inflammatory mediators such as cytokines and chemokines (11) .
NF-kB is a family of inducible transcription factors comprised of five structurally related proteins that form homodimers and heterodimers in mammalian cells (12) . These NFkB dimers are inactive in the cytoplasm through binding to a family of inhibitor molecules (IkB). When cells are engaged with extracellular stimuli, IkB is phosphorylated and undergoes ubiquitination and proteasomal degradation, leading to the release of NF-kB. Then, NF-kB proteins translocate to the nucleus and bind to targeted deoxyribonucleic acid (DNA) sequences, upregulating the expression of a wide range of genes critical to host defense and the inflammatory response (12) . Therefore, inhibiting NF-kB activity is a rational strategy for controlling the cytokine storm in sepsis.
Ubiquitination of IkB plays a key role in its degradation and subsequently the activation of NF-kB. Ubiquitination is a posttranslational modification that occurs through a multistep enzymatic process that attaches a small ubiquitin protein covalently on a lysine residue of a substrate protein (13) . The process is initiated by a ubiquitin-activating (E1) enzyme that uses ATP to activate ubiquitin for conjugation and transfers it to a ubiquitin-conjugating (E2) enzyme. The E2 enzyme then interacts with a ubiquitin ligase (E3) and transfers the ubiquitin to the target protein (13). The ubiquitinated proteins are then
Animal model of sepsis
Male C57BL/6 mice (20 g-25 g) were obtained from Taconic (Albany, NY) and sepsis was induced by cecal ligation and puncture (CLP). Before operation, mice were anesthetized by isoflurane inhalation, and the abdomen was shaved and washed with 10% povidone iodine. An incision was made and the cecum was ligated using 4-0 silk suture and double-punctured with a 22-gauge needle. Animals were administered 20% dimethyl sulfoxide in normal saline (vehicle) or 5 mg/kg body weight PYR-41 (Tocris, Park Ellisville, Mo) by intravenous injection immediately after CLP. Mice were resuscitated with 0.5 mL normal saline by subcutaneous injection immediately after surgery. At 20 h after CLP, blood and tissues were collected for various analyses. For the survival study, mice were administered the broad-spectrum antibiotic Primaxin (0.5 mg/kg; Merck, Kenilworth, NJ) subcutaneously after CLP. The animals were monitored for 10 days to record survival. All the experiments were performed in accordance with the guidelines for the use of experimental animals by the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee of The Feinstein Institute for Medical Research.
Measurements of cytokines and organ injury markers
Tumor necrosis factor (TNF)-a, interleukin (IL)-1b, and IL-6 were quantified using specific mouse enzyme linked immunosorbent assay kits (BD Biosciences, Franklin Lakes, NJ). Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) were measured using commercial assay kits (Pointe Scientific, Lincoln Park, Mich).
Histopathologic examination
Lung tissues were fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin. Morphologic examination of these tissues was performed under a light microscope in a blinded manner. The severity of lung injury was judged by a semiquantitative scoring system according to the following pathological features: focal alveolar membrane thickening, capillary congestion, intra-alveolar hemorrhage, interstitial neutrophil infiltration, and intra-alveolar neutrophil infiltration. Each feature was scored from 0 to 3 based on its absence (0) or presence to a mild (1), moderate (2), or severe (3) degree, and a cumulative total histology score was determined (16) .
Myeloperoxidase (MPO) activity assay
Lung tissues were homogenized in potassium phosphate buffer containing 0.5% hexa-decyl-trimethyl-ammonium bromide. After centrifugation, the supernatant was diluted in reaction solution, and the rate of change in optical density for 2 min was measured at 460 nm to calculate myeloperoxidase (MPO) activity.
Western blotting analysis
Tissue and cell lysates were homogenized in lysis buffer (10 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate) containing a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, Ind) by sonication. Total protein was fractionated on Bis-Tris gels (4% to 12%) and transferred to nitrocellulose membranes. Nitrocellulose membranes were blocked by incubation in Tris buffered saline with Tween (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.1% Tween 20) containing 10% non-fat dry milk for 1 h. Membranes were incubated with anti-IkB (Santa Cruz Biotechnology, Santa Cruz, Calif), anti-cleaved caspase-3, or anti-b-actin (Sigma, St Louis, Mo) antibodies overnight at 48C, followed by incubation with HRP-conjugated secondary antibody for 1 h. Specific proteins were visualized by using Pierce ECL2 Western Blotting Substrate (Thermo Scientific, Southfield, Mich) or Luminata Forte Western HRP Substrate (Millipore, Billerica, Mass). Band densities were determined using a Bio-Rad image system.
Quantitative polymerase chain reaction analysis
Total RNA was extracted from lung tissues using a Trizol reagent (Invitrogen, Carlsbad, Calif) and was reverse-transcribed into cDNA using murine leukemia virus reverse transcriptase (Applied Biosystems, Foster City, Calif). A polymerase chain reaction (PCR) reaction was carried out in 25 mL of a final volume containing 0.08 mmol of each forward and reverse primer, cDNA, and 12.5 mL SYBR Green PCR Master Mix (Applied Biosystems). Amplification was conducted in an Applied Biosystems 7,300 real-time PCR machine under the thermal profile of 508C for 2 min, 958C for 10 min followed by 45 cycles of 958C for 15 sec and 608C for 1 min. The level of mouse b-actin mRNA was used for normalization. Relative expression of mRNA was expressed as the fold change compared with the sham. The primers used for this study are listed in Table 1 .
Terminal deoxynucleotidyl transferase deoxyuridine 5-triphosphate nick end-labeling (TUNEL) assay
Tissue slides were dewaxed and incubated with proteinase K. Slides were then stained using a TUNEL kit (Roche Diagnostics), counterstained with propidium iodide and examined under a fluorescence microscope. Apoptotic cells appeared green fluorescent and were counted across 10 visual fields at Â200 magnification.
Statistical analysis
Data are expressed as mean AE standard error and compared with one-way analysis of variance and the Student-Newman-Keuls test for multiple group analyses. The survival rate was estimated by the Kaplan-Meier method, and rates were compared using the log-rank test. Differences in values were considered significant if P < 0.05.
RESULTS

PYR-41 inhibits cytokine production in macrophages stimulated with LPS
In sepsis, release of proinflammatory cytokines from macrophages is the main cause of the ''cytokine storm'' (8) . We first determined the effectiveness of PYR-41 in attenuating NF-kB activation in macrophages. The expression levels of IkB, an NF-kB inhibitor, in RAW 264.7 cells were decreased by 54% at 30 min after lipopolysaccharide (LPS) stimulation (Fig. 1A) . With PYR-41 treatment at 10 mM and 20 mM, the expression levels of IkB were restored to 89% and 95% of those in the non LPS-stimulated RAW 264.7 cells, respectively (Fig. 1A) . We then measured the TNF-a levels in cultured media grown with RAW 264.7 cells. After 4 h LPS stimulation, the TNF-a levels increased from 0.03 ng/mL to 1.34 ng/mL, while treatment with PYR-41 at doses of 5 mM, 10 mM, and 20 mM decreased TNF-a levels by 38%, 81%, and 94%, respectively (Fig. 1B) . We also examined the viability of RAW 264.7 cells by MTS assay and observed no adverse effects of PYR-41 on cell viability (Fig. 1C) .
PYR-41 treatment attenuates systemic inflammation and organ injury markers in septic mice
After demonstrating PYR-41's inhibition of cytokine production in vitro, we then administered PYR-41 to mice that underwent sepsis-induction by CLP. At 20 h after CLP, serum levels of proinflammatory cytokines TNF-a, IL-1b, and IL-6 were markedly increased compared with the sham (Fig. 2 , A-C). In contrast, treatment with PYR-41 significantly reduced their levels by 79%, 77%, and 89%, respectively, compared with the vehicle (Fig. 2 , A-C). Serum levels of organ injury markers AST, ALT, and LDH were also elevated after CLP, while their levels were reduced by 27%, 43%, and 52%, respectively, with PYR-41 treatment (Fig. 2, D-F) .
PYR-41 treatment prevents lung injury in septic mice
The lungs are one of the most vulnerable organs affected during sepsis (17) . We first performed histologic examination of the lung tissues at 20 h after CLP and observed substantial morphologic changes in the vehicle group, including alveolar collapse, edema, hemorrhage, and infiltration of inflammatory cells compared with the sham (Fig. 3A) . After treatment with PYR-41, the morphologic appearance of lung tissues was improved (Fig. 3A) . We further graded the severity of the lung damage and showed a 74% reduction in histology injury score in the treatment group compared with the vehicle (Fig. 3B) . Excessive immune cell infiltration, especially by neutrophils, is one important factor causing lung injury in sepsis (18) . Lung MPO activity, a marker of neutrophil infiltration (19) , was markedly increased after CLP by 19-fold compared with the sham, while it was significantly reduced by 64% with PYR-41 treatment compared with the vehicle (Fig. 3C) .
We also assessed apoptosis in the lung by performing a TUNEL assay on the tissue sections. As shown in Figure 4A , the TUNEL-positive cells in the vehicle were well detected, while they were barely seen in the sham. Treatment with PYR-41 significantly reduced the number of TUNEL-positive or apoptotic cells in the lungs (Fig. 4, A and B) . In addition, we examined the expression of cleaved caspase-3, another marker of apoptosis (20) , in the lungs by Western blotting. The levels of cleaved caspase-3 expression were significantly increased after CLP, but reduced with PYR-41 treatment to levels comparable to the sham (Fig. 4C) . IL-1b  NM_008361  CAGGATGAGGACATGAGCACC  CTCTGCAGACTCAAACTCCAC  IL-6  NM_031168  CCGGAGAGGAGACTTCACAG  CAGAATTGCCATTGCACAAC  KC  NM_008176  GCTGGGATTCACCTCAAGAA  ACAGGTGCCATCAGAGCAGT  MIP-2  NM_009140  CCCTGGTTCAGAAAATCATCCA  GCTCCTCCTTTCCAGGTCAGT  COX-2  NM_011198  CTCAGCCAGGCAGCAAATC  ACATTCCCCACGGTTTTGAC  iNOS  NM_010927  GCAGGTCGAGGACTATTTCTTTCA 
PYR-41 treatment inhibits inflammation in the lungs of septic mice
After demonstrating the protective effect of PYR-41 on the lungs of septic mice, we examined the status of NF-kB activation by assessing the expression levels of IkB using Western blotting. The levels of IkB were reduced in the vehicle group compared with the sham, while its levels in the PYR-41 treatment group were returned to the sham level (Fig. 5) . Consequently, we measured the expression of proinflammatory cytokines IL-1b and IL-6, target genes of the NF-kB signaling pathway, in the lungs. The mRNA and protein levels of both cytokines were markedly elevated after CLP, while levels of IL-1b and IL-6 were significantly reduced by PYR-41 treatment, ranging from a 62% to 87% reduction compared with the vehicle (Fig. 6, A-D) .
We also determined the expression of proinflammatory chemokines keratinocyte-derived chemokine (KC) and macrophage inflammatory protein 2 (MIP-2), additional target genes of the NF-kB signaling pathway. Similar to cytokines, mRNA levels of both chemokines in the lungs were increased after CLP, but inhibited with PYR-41 treatment (Fig. 6, E and F) .
PYR-41 treatment decreases the expression of inflammatory mediators in the lungs of septic mice
In the inflammatory cascade, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) are important mediators and contribute to organ injury (21) . We next measured mRNA levels of both molecules in the lungs by quantitative polymerase chain reaction. At 20 h after CLP, the level of COX-2 mRNA was increased by 3.4-fold compared with the sham, while its level was reduced by 56% with PYR-41 treatment (Fig. 7A) . Likewise, the level of iNOS mRNA was increased by 8.6-fold compared with the sham, while its level was reduced by 72% with PYR-41 treatment (Fig. 7B) .
PYR-41 treatment improves survival in septic mice
Lastly, we performed a 10-day survival study to evaluate the overall beneficial effect of PYR-41 in sepsis using a mouse CLP model. When administered immediately after CLP, PYR-41 significantly increased the survival rate from 42% in the vehicle group to 83% (Fig. 8) . When administered 5 h after CLP, PYR-41 increased the survival rate to 67%, although this did not reach statistical significance (Fig. 8) .
DISCUSSION
Current management of septic patients is supportive in nature, and no effective pharmacotherapies are available with the exception of early administration of antibiotics. Despite the gap in the translation of laboratory findings to the clinical setting, identifying pharmacological targets remains a high priority for the development of effective therapies for sepsis. In sepsis, patients will develop hyperinflammation against infection, which leads to multiple organ dysfunction (22) . It is well understood that activation of the transcription factor NFkB plays a crucial role in regulating the production of proinflammatory cytokines and mediators during sepsis (22) . In this study, we evaluated the effect of ubiquitination inhibition on inflammation and organ injury in sepsis using a CLP mouse model, which is a clinically relevant model to mimic human sepsis (23) .
LPS is the major component of the outer membrane of gramnegative bacteria and activates the NF-kB pathway in various cell types leading to the release of proinflammatory cytokines in the host (24) . By using an in vitro cell culture system, we first demonstrated that PYR-41 treatment inhibits TNF-a production in LPS-stimulated macrophages in a dose-dependent manner. We also demonstrated that the degradation of IkB is inhibited in LPS-stimulated macrophages after PYR-41 treatment. In the study by Yang et al. (15), they have used an in vitro ubiquitylation reaction assay to demonstrate the specificity of PYR-41 in inhibiting ubiqutin E1 enzyme activity. Consistently, they have also shown that PYR-41 treatment prevents IkB degradation in cancer cells stimulated with IL-1a and TNF-a (15) . It also reports that PYR-41 treatment induces cell death in transformed cells in a dose-dependent manner, but has much less of an effect on untransformed cells (15) . In this study, we did not observe the effect of PYR-41 treatment on macrophage viability, which also indicates that the reduction of TNF-a levels by PYR-41 is not due to a decrease in macrophage number in the assay.
Based on PYR-41's effectiveness in inhibiting cytokine production in vitro, we then sought to administer it in an animal model of sepsis. By analyzing serum samples from septic mice, we showed that the levels of inflammatory cytokines TNF-a, IL-1b, and IL-6 are significantly reduced with PYR-41 treatment. The synthesis of these three cytokines is known to be mediated by the NF-kB pathway (25) . This result indicates that administration of PYR-41 is effective in blocking downstream events of NF-kB activation in the inflammatory response in animals. Subsequently, we demonstrated that several serum organ injury markers (AST, ALT, and LDH) are also attenuated in septic mice after PYR-41 treatment, validating the link between hyperinflammation and multiple organ injury in sepsis.
At the organ level, we examined the lung in septic mice. After CLP, the lung tissues demonstrated severe damage on histologic analysis. With PYR-41 treatment, the structural integrity of the lung was better preserved, with statistically significant improvement in histology score. Apoptosis is an important contributor to lung injury, and inflammation is a major inducer of apoptosis (26) . By using TUNEL assay and Furthermore, we demonstrated that PYR-41 treatment restored expression levels of IkB in the lungs of septic mice. The decrease of IkB levels may be due to its degradation triggered by the ubiquitination. It has been reported a marked increase in accumulation of ubiquitinated proteins in the lungs of septic mice (27) . Therefore, PYR-41 treatment can effectively reduce the IkB ubiquitination and subsequently its degradation, leading to inhibition of NF-kB activation. Similarly to systemic inflammation, we also demonstrated that mRNA and protein levels of IL-1b and IL-6 in the lungs are significantly reduced with PYR-41 treatment. NF-kB plays a key role in controlling lung injury. A study has also shown that targeting the NF-kB pathway by administering an IkB kinase inhibitor can reduce the severity and prevent the progression of lung injury in mice in an LPS pump model (28) .
In addition to cytokines, we also examined the levels of chemokines KC and MIP-2 in the lungs. The transcriptional regulation of both chemokines can be mediated through NF-kB (29) . Consistently, we demonstrated that PYR-41 treatment significantly inhibits the elevation of KC and MIP-2 mRNA levels in septic mice. It has also been reported that KC and MIP-2 are sufficient to induce neutrophil recruitment to the lung (30, 31) . Indeed, we observed an increase in neutrophil infiltration (MPO activity) in the lungs of septic mice, which was reduced by PYR-41 treatment. Due to the release of proteolytic enzymes and reactive oxygen species, excessive infiltration of neutrophils disrupts the endothelial barrier and causes tissue damage (18, 32) . COX-2 and iNOS are additional inflammatory mediators that we have examined in the lungs. The promoters of COX-2 and iNOS contain NF-kB binding sites (33, 34) . We also observed upregulation of mRNA levels of these mediators in the lungs of septic mice, whereas their levels were significantly inhibited by PYR-41 treatment. It has also been reported that administration of a selective COX-2 inhibitor ameliorates inflammation, injury, and sepsis-associated mortality in an animal model (35) . Elevation of iNOS expression can lead to increased production of nitric oxide and formation of highly reactive peroxynitrite, which causes tissue damage and organ failure (36) .
In addition to ubiquitin-tagging, protein turnover is also regulated by proteasome degradation (37) . These two successive processes are known as the ubiquitin-proteasome pathway (UPP) (37) . Several inhibitors targeting the proteasome have been developed as therapeutic agents, including bortezomib, which is approved by the Food and Drug Administration for the treatment of multiple myeloma (38) . When using a proteasome inhibitor to study UPP, IkB was the first substrate to be identified (39) . Thus, the potential of using these proteasome inhibitors for treating various inflammatory diseases has been Mice were subjected to CLP with intravenous injection of vehicle (20% DMSO in saline; white circle), PYR-41 (5 mg/kg) immediately (black circle), or PYR-41 (5 mg/kg) at 5 h (gray circle) after CLP. Mice were observed for 10 days to record the mortality. Survival rates were analyzed by the Kaplan-Meier estimator using a log-rank test. * P < 0.05 versus vehicle. DMSO indicates dimethyl sulfoxide.
evaluated (40) , including the use of MG132 for sepsis treatment in the CLP model (41) . The success of proteasome inhibitors for clinical use holds promise for the further development of ubiquitination inhibitors as therapeutic agents to target UPP. However, ubiquitination is a basic mechanism for controlling protein turnover in various types of cells. The toxicity and adverse effects of targeting ubiquitination need to be carefully evaluated for clinical use. Furthermore, whether PYR-41 has targets other than the NF-kB pathway requires further investigation. Another concern is that the use of anti-inflammatory drugs may lead to susceptibility to secondary infection and worsen wound healing in septic patients. However, careful control of the dose and timing of anti-inflammatory drug administration may be achieved to balance immune system functions and provide an overall beneficial outcome for patients.
In summary, by administering PYR-41 to restore the expression of IkB, an NF-kB inhibitor, we have demonstrated its effect on attenuating systemic inflammation and general organ injury in septic mice. At the organ level, we have shown an improvement in morphologic integrity, a reduction in proinflammatory cytokine and chemokine levels, and an inhibition of neutrophil infiltration in the lungs with PYR-41 treatment. Finally, we have demonstrated that administration of PYR-41 immediately and at 5 h after CLP improve the overall survival of septic mice. Although there is a gap in the translation of animal studies to clinical outcomes, targeting UPP by PYR-41 inhibition of the NF-kB pathway as demonstrated here is an initial step in the development of novel therapeutic agents to treat sepsis.
